Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Kosan, Roche ending cancer deal

KOSN and Roche (SWX:ROG) will end a 2002 deal to develop and commercialize epothilone compounds to

Read the full 166 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE